Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more

Recent & Breaking News (NDAQ:IBRX)

NantKwest to Present at the 37th Annual Canaccord Genuity Growth Conference

Business Wire August 7, 2017

NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies

Business Wire July 31, 2017

Haeggquist & Eck Investigates NantKwest for Misrepresenting Compensation to CEO by $49 Million and Breach of Fiduciary Duty

Business Wire July 27, 2017

NantKwest Announces Publication of Preclinical Data of haNK Cell Therapy in Combination with Checkpoint Inhibitor Avelumab Providing Strong Rationale for Advancement to Human Clinical Trials

Business Wire July 25, 2017

Haeggquist & Eck, LLP Investigates NantKwest Inc. for Potential Breaches of Fiduciary Duty by Its Board of Directors

Business Wire July 14, 2017

Daily Technical Summary Reports on Biotech Stocks -- Juno Therapeutics, Lexicon Pharma, NantKwest, and Nektar Therapeutics

PR Newswire July 7, 2017

10 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  June 20, 2017

15 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  June 13, 2017

NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of Disease

Business Wire June 6, 2017

NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017

Business Wire June 2, 2017

NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs

Business Wire May 18, 2017

NantKwest Appoints Dr. Leonard Sender as Senior Vice President of Medical Affairs for Pediatric, Adolescent and Young Adult Oncology

Business Wire May 16, 2017

NantKwest to Present at 2017 Bank of America Merrill Lynch Healthcare Conference

Business Wire May 15, 2017

NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer

Business Wire May 9, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

GlobeNewswire April 4, 2017

NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma

Business Wire March 20, 2017

NantKwest to Present at Upcoming Investor Conferences

Business Wire March 6, 2017

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  January 24, 2017

Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer

Business Wire January 23, 2017

NantKwest to Host 2nd Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs

Business Wire December 19, 2016